blend

CJC-1295 (no DAC) + Ipamorelin

A mix of two lab-made peptides meant to raise growth hormone; neither is approved, and the pair has never been studied together.

A two-peptide mix of Modified GRF (1-29) and the ghrelin-receptor agonist ipamorelin; neither ingredient is an approved drug, an FDA advisory committee voted against both for pharmacy compounding, and no study has tested the pair together.

Data refreshed 2026-11-01 · Based on 9 published references

At a glance

FDA approved

No.

Potential results

No study has tested this mix
Ipamorelin: short burst of growth hormone in healthy men (small study)
Ipamorelin: no clear help after bowel surgery (trial vs placebo)
CJC-1295 without DAC: never tested in people

Unverified, online reports only: deeper sleep, better recovery and changes in body composition.

Dose

Study doses: see the Scientific view
Converter: mg, mL and syringe units

Storage

Powder: fridge (2–8 °C) for the short term, freezer (−20 °C) for the long term; after mixing, fridge for up to 28 days (general guidance, not tested for this compound).

A summary of the sources on this page, not medical advice.

Names

Also called: CJC-1295/ipamorelin, CJC/Ipa, Mod GRF 1-29 + ipamorelin, CJC-1295 no DAC with ipamorelin

Regulatory (US)

FDA approval: none

503A compounding: unknown
Not on any FDA compounding list; see Regulatory picture.

Molecule

Origin

Components

This is a blend. Each ingredient is broken down below and on its own page: cjc-1295-no-dac, ipamorelin

What is inside

Products sold under this name put two lab-made peptides in one vial. A peptide is a short chain of amino acids (the building blocks of protein).

The first is CJC-1295 without DAC. It is also called Modified GRF (1-29). It copies the working front part of a brain signal called growth hormone-releasing hormone (GHRH). Four of its building blocks are swapped.

The second is ipamorelin. It is a chain of five building blocks. It works on the ghrelin receptor (a “switch” on cells).

Both tell the pituitary gland to release the body’s own growth hormone. But they use two different switches.

There is no standard recipe. FDA reviews found at least two. One was an injection made by a large pharmacy in 2019–2020. It had 6 mg/mL of CJC-1295 and 15 mg/mL of ipamorelin. The other was a pharmacy listing with 6 mg of each per vial. No approved medicine contains either peptide. No study has tested the mix.

Component 1 is [D-Ala2, Gln8, Ala15, Leu27]-hGRF(1-29)-NH2 (C152H252N44O42, 3367.9 g/mol), a GHRH-receptor agonist lacking the maleimidopropionyl-lysine that lets the DAC version bind albumin. Component 2 is Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C38H49N9O5, 711.9 g/mol), a GHS-R1a agonist.

FDA’s 2024 CJC-1295 briefing records that one outsourcing facility reported compounding, in 2019 and 2020, a multiple-ingredient injection powder containing CJC-1295 6 mg/mL and ipamorelin 15 mg/mL, roughly a 12:1 molar excess of ipamorelin; no outsourcing facility reported CJC-1295 products after 2020. FDA’s ipamorelin briefing cites a pharmacy listing for a “CJC-1295/ipamorelin (lyo) 6/6 mg vial”, about 4.7:1 by moles, and a 2020 M-CERSI report in which a subject-matter expert described a “trending” synergistic combination of ipamorelin acetate with CJC-1295 without DAC.

Salt form (free base or acetate) and identity are not standardised. FDA found at least nine names in use for five CJC-1295-related substances, so the CJC-1295 component of a given product may be either peptide.

Ingredient: CJC-1295 without DAC

This is a copy of the working part of GHRH. It is 29 building blocks long. GHRH is the brain signal that tells the pituitary to release growth hormone. Four building blocks are swapped for ones the body breaks down more slowly.

It is not sermorelin. Sermorelin is the unchanged chain that was once an approved drug. CJC-1295 without DAC also lacks the chemical hook that makes CJC-1295 with DAC last about a week.

There is almost no published research on it. The FDA’s 2024 review found no studies of how it works. There are no registered human trials. No one has measured how long it lasts in the body. Everything said about its effects is borrowed from similar molecules. If it works like other GHRH copies, it only works when the pituitary gland is working.

The substitutions address known weak points of GRF(1-29): D-Ala2 resists dipeptidyl peptidase-IV cleavage of the Ala2–Asp3 bond, Gln8 replaces deamidation-prone Asn8, Ala15 replaces Gly15, and Leu27 replaces oxidation-prone Met27. It is presumed to act on the GHRH receptor, a Gs-coupled receptor on somatotrophs that raises cAMP and stimulates GH synthesis and release, subject to somatostatin and IGF-1 feedback.

FDA’s December 2024 briefing states that the nominations did not include, and FDA had not identified, pharmacological studies of CJC-1295 free base or acetate, nor nonclinical pharmacokinetic studies. Its safety assessment therefore drew on the DAC literature and on the expected effects of raising endogenous GH. ClinicalTrials.gov lists no study of the non-DAC peptide; the only CJC-1295 registration, NCT00267527, used ConjuChem’s DAC conjugate and was terminated in 2006 after a participant’s death. Potency and half-life relative to sermorelin are unmeasured.

See the CJC-1295 without DAC article for sources and detail.

Ingredient: Ipamorelin

Ipamorelin is a chain of five building blocks. Novo Nordisk designed it in the 1990s. It works on the ghrelin receptor. This is the same switch used by the stomach’s “hunger hormone”. That switch also tells the pituitary to release growth hormone.

In pigs, it released growth hormone without raising stress hormones such as cortisol. Older compounds did raise them.

Healthy men were given it into a vein through a drip. Their growth hormone rose to one short peak. It fell back within about six hours.

Its main patient trial was in people recovering from bowel surgery. It did not show a clear, reliable difference from a dummy treatment (placebo). Work on it as a drug then stopped. There are no controlled human studies of injecting it under the skin. That is how these products are meant to be used.

Ipamorelin (NNC 26-0161) is a GHS-R1a agonist; GHS-R1a is a Gq-coupled receptor on somatotrophs and hypothalamic neurons. Raun et al. (1998) reported an EC50 of 1.3 nmol/L for GH release from rat pituitary cells and an ED50 of 2.3 nmol/kg in conscious swine, with no rise in ACTH or cortisol beyond GHRH-like levels even at more than 200 times the GH ED50; GHRP and GHRH antagonist experiments placed its action at the GHRP receptor.

FDA’s 2024 briefing summarises human intravenous pharmacokinetics (Gobburu et al. 1999): terminal half-life about 2 hours and a GH peak at about 0.67 hours returning to very low levels by 6 hours. In the Phase 2 postoperative ileus trial (Beck et al. 2014, NCT00672074; 0.03 mg/kg IV twice daily), median time to first tolerated meal was 25.3 versus 32.6 hours on placebo (P = 0.15); hypokalaemia and hyperglycaemia were more frequent on ipamorelin, and two ipamorelin-treated patients died after anastomotic leak, relationship unclear.

See the ipamorelin article for sources and detail.

Why researchers might study these together

Growth hormone release has two “go” signals and one “stop” signal. The go signals are GHRH and a ghrelin-type signal. The stop signal is a hormone called somatostatin.

The two ingredients press different go signals. So the idea is that together they may do more than either one alone.

There is some support for this idea from similar molecules. A 1990 study had 18 healthy men. They got small doses of GHRP-6 (a ghrelin-type peptide) with natural GHRH. Together, the two released more growth hormone than they would separately. A 2009 study in 47 men used GHRP-2 with GHRH. It also found a boost from the pair. In mice with no GHRH of their own, the ghrelin-type drug alone did not release growth hormone.

This exact pair has never been tested together in published human or animal studies. So any combined effect, safe dose or risk is only a guess.

The GHRH receptor (Gs, cAMP/PKA) and GHS-R1a (Gq, phospholipase C, intracellular calcium) converge on somatotroph GH exocytosis, and GHS-R1a agonists also act at the hypothalamus. Bowers et al. (JCEM 1990; 18 men) gave GHRP-6 at 0.1, 0.3 and 1.0 µg/kg IV: mean peak GH was 7.6, 16.5 and 68.7 µg/L versus 1.2 on placebo, and the submaximal doses combined with GHRH(1-44) 1 µg/kg released GH synergistically, which the authors read as evidence that the two act independently. Veldhuis and Bowers (2009; 47 men aged 18–74, simultaneous GHRH and GHRP-2 infusion under a sex-steroid clamp) found synergy correlated negatively with age and abdominal visceral fat and positively with IGF-I (all P under 0.001). In GHRH-knockout mice, five weeks of the GHRH analogue JI-38 plus GHRP-2 produced greater body length and weight than JI-38 alone, while GHRP-2 alone gave no acute GH response (Fintini 2005).

Extrapolation is limited: ipamorelin is more selective than GHRP-6 or GHRP-2, Modified GRF(1-29) is neither GHRH(1-44) nor JI-38, and the non-DAC peptide has no pharmacokinetic data. ClinicalTrials.gov lists no trial combining the two, and a PubMed search for both names returned only reviews and doping-control methods.

Regulatory picture

Approval: neither ingredient is in any FDA-approved medicine. No one has asked the FDA to approve the combination.

Pharmacy mixing (compounding): in September 2023 the FDA put both peptides in Category 2. This is its list of substances that raise significant safety concerns. The groups that had proposed them withdrew in 2024.

The FDA’s advisory committee then voted on whether pharmacies may mix them. It voted against both. For ipamorelin the vote was 12 to 0 against, with one person abstaining. For the two forms of CJC-1295 without DAC, the votes were 13 to 0 and 12 to 1 against. No final rule has followed. Ipamorelin acetate is still in Category 2 for large outsourcing facilities. Neither peptide was among the six peptides in the US health department’s October 2026 draft policy easing enforcement, and that policy covers single-ingredient products only, so a blend is outside it.

Enforcement: a 2022 FDA inspection recorded a pharmacy making this combination. It used CJC-1295 that was not pharmaceutical grade.

Sport: WADA (the World Anti-Doping Agency) bans both ingredients at all times.

Approval: none. Neither CJC-1295 without DAC nor ipamorelin is a component of an FDA-approved drug or has a USP monograph, so a compounded combination cannot meet section 503A(b)(1)(A)(i) unless both substances are added to the 503A bulks list in 21 CFR 216.23.

Compounding: “CJC-1295” (form unspecified) and ipamorelin acetate entered 503A Category 2 on 2023-09-29 and were removed on 2024-09-27 after the nominations were withdrawn. FDA then evaluated CJC-1295 free base and acetate, and ipamorelin free base and acetate, on its own initiative and proposed that none be listed, citing identity and impurity concerns, immunogenicity, the absence of pharmacology and efficacy data for the non-DAC peptide, and the failed intravenous ileus trial and adverse events for ipamorelin. The committee votes were 0–12–1 for each ipamorelin form (2024-10-29) and 0–13 and 1–12 for CJC-1295 free base and acetate (2024-12-04). FDA’s safety-risk page, updated 2026-04-22, lists ipamorelin acetate in 503B Category 2. Neither substance was on the agenda of the July 2026 committee meeting. Neither CJC-1295 nor ipamorelin is among the six peptides covered by the HHS draft enforcement-discretion policy of 2026-10-30 (docket HHS-OASH-2026-0496), which in any case applies only to single-active-ingredient products. The compounding field follows the stricter component and is recorded as unknown, as for both ingredients.

Sport: WADA 2026 S2.2.4 lists CJC-1295 and ipamorelin.

Dose

Doses reported in trials and studies

How dosing worked in the studies

No study has given the two peptides together. No human doses of CJC-1295 without DAC are on record. The only human doses listed here are for ipamorelin alone. They come from a 1999 study by Gobburu and colleagues. The study was not registered. Healthy men got ipamorelin into a vein over 15 minutes. There were five dose levels, with eight men at each: 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg. Each group got one dose level. The study looked at how the body handled the drug and how growth hormone responded. It was not designed to show whether it was safe or whether it helped.

Doses used in the studies are in the Scientific view.

Study doses are not personal dosing instructions. Reading doses safely: how concentration and syringe markings work.

Doses reported in studies, exactly as the cited trial reported them. They are not personal dosing instructions. Population, route and schedule matter more than the number.

No registered clinical trials are catalogued for this compound. The doses below come from other published studies in people.

Doses in other published studies

Published studies not listed in the trials table above: smaller or unregistered human studies first, then animal and cell studies. Doses are shown exactly as each study reported them. Animal studies report weight-based doses, absolute amounts or concentrations; none translates directly to people, and none is converted here.

Subjects	Design	Dose	Finding	Source
Humans: healthy men, eight per dose level at five dose levels. Ingredient: ipamorelin	Dose-escalation pharmacokinetic/pharmacodynamic study (not registered)	4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg infused over 15 minutes, one dose level per group	Pharmacokinetics were dose-proportional with a terminal half-life of 2 hours, and GH was released in a single episode that peaked at 0.67 hours and declined to negligible levels at all doses.	Gobburu JV et al., Pharm Res, 1999
Rats: Wistar, 200–300 g body weight, one compound per animal. Ingredient: CJC-1295 without DAC, identified by the authors as (D-Ala2, Gln8, Ala15, Leu27)-GRF amide	Doping-control method development with a qualitative rat administration study	0.1 mg intravenous, single injection; blood sampled 2, 4 and 8 hours after injection	Intact peptide was detected in rat plasma 2, 4 and 8 hours after dosing; the authors state that only qualitative results were obtained and no pharmacokinetic interpretation was made, and no GH measurements were reported.	Knoop A et al., Anal Bioanal Chem, 2016
Rats: adult females. Ingredient: ipamorelin	Controlled dose-response study with vehicle group	0, 18, 90 or 450 µg/day, subcutaneous, given as three injections daily for 15 days	Longitudinal bone growth rate rose dose-dependently from 42 µm/day on vehicle to 44, 50 and 52 µm/day, with greater body-weight gain and no change in total IGF-I.	Johansen PB et al., Growth Horm IGF Res, 1999
Rats: 13-week-old female Sprague-Dawley (n=7 on ipamorelin). Ingredient: ipamorelin	Controlled study versus vehicle, GHRP-6 and GH	0.5 mg/kg per day, continuous subcutaneous infusion by osmotic minipump for 12 weeks	Body weight and tibial and vertebral bone mineral content rose versus vehicle, but bone mineral content corrected for body weight and volumetric bone density were unchanged.	Svensson J et al., J Endocrinol, 2000
Rats: 8-month-old females, glucocorticoid model. Ingredient: ipamorelin	Controlled study of ipamorelin alone, methylprednisolone alone, or both	100 µg/kg subcutaneous three times daily for 3 months (with or without methylprednisolone 9 mg/kg/day)	Compared with glucocorticoid alone, the combination increased maximum calf-muscle tetanic tension and raised periosteal bone formation rate four-fold.	Andersen NB et al., Growth Horm IGF Res, 2001
Rats: fasted males, postoperative ileus model (laparotomy and intestinal manipulation). Ingredient: ipamorelin	Controlled study versus saline and GHRP-6	0.01–1 mg/kg by intravenous bolus infusion, as a single dose or four doses a day at 3-hour intervals for 2 days	A single 1 mg/kg dose shortened time to first bowel movement, and repeated 0.1 or 1 mg/kg dosing increased cumulative fecal output, food intake and body-weight gain over 48 hours.	Venkova K et al., J Pharmacol Exp Ther, 2009

Doses described in clinical or compounding practice

From FDA labels and documents, other regulators, published reviews and professional references, as each source states them. Unless a source says otherwise, these describe practice or proposals, not results tested in trials. Reading doses safely: how concentration and syringe markings work.

FDA's December 2024 CJC-1295 briefing summarises what websites say. Several of the pages it cites are CJC-1295/ipamorelin pages. Most say CJC-1295 is given as an SC injection at night, some say only 5 out of 7 nights a week, and one says once weekly. FDA records doses 'from 100 mcg per week to 100-400 mcg per day', one website's maximum weekly dose of 2000 mcg, and, for fitness and bodybuilding, 'from 250 mcg per day to 100-200 mcg 2-3 times a day.' These are marketing claims, not studied doses. FDA notes that most websites do not give the form of CJC-1295, and it identified no pharmacological studies of CJC-1295 (free base) or CJC-1295 acetate. (FDA briefing document: CJC-1295-related bulk drug substances, Pharmacy Compounding Advisory Committee, December 4, 2024, FDA document)
FDA's transcript of the December 4, 2024 CJC-1295 open public hearing records two speakers. Jim LaValle, chair of the International Peptide Society, said of CJC acetate that across the '9 pharmacies that we surveyed, the dosing was typically at 100 micrograms once or twice a day.' Clinician Terri DeNeui presented 508 patients from three internal medicine clinics plus data from a pain-management clinic, and said 'These doses were 100 micrograms subQ once a night in all these patients presented.' These are unverified statements by speakers, not FDA findings, and neither speaker mentioned ipamorelin. (Transcript (morning session, Topic 1: CJC-1295-related bulk drug substances), Pharmacy Compounding Advisory Committee, December 4, 2024, FDA document)
This FDA-funded report was prepared for FDA by the University of Maryland's M-CERSI, and it states that its contents do not necessarily represent FDA's official views. It records one subject-matter expert, among urologists discussing use for growth hormone deficiency, describing a 'trending' synergistic combination of ipamorelin acetate with CJC-1295 that is 'administered via once daily injection, at night.' Practitioners track IGF-1 levels and adjust the dose based on them. The report gives no amounts. FDA's CJC-1295 briefing says the expert did not say which form of CJC-1295 was used, while FDA's ipamorelin briefing footnotes it as CJC without DAC. (Ipamorelin acetate: Summary Report (Gianturco SL et al., University of Maryland M-CERSI, prepared for FDA, December 2020), FDA document)
FDA's October 2024 ipamorelin briefing records a wellness clinic marketing ipamorelin acetate as SC solutions '(supplied as a dose of 150 mcg per day via single injections).' This is ipamorelin on its own, not the blend. The same briefing states that FDA did not identify PK or PD information for the proposed SC route. The only human PK/PD data it describes are for intravenous use (Gobburu et al. 1999). (FDA briefing document: ipamorelin-related bulk drug substances, Pharmacy Compounding Advisory Committee, October 29, 2024, FDA document)

How the blend's ratio compares with studied doses

In the threads reviewed, pre-mixed vials were described as equal masses of each peptide (for example 5 mg/5 mg) or, in one case, 6 mg CJC-1295 with 15 mg ipamorelin; FDA's 2024 reviews cite a 6 mg/6 mg vial listing and an outsourcing-facility injection with 6 mg/mL CJC-1295 and 15 mg/mL ipamorelin, and because ipamorelin is about one-fifth the molecular weight, an equal-mass mix holds roughly 4.7 ipamorelin molecules per CJC-1295 molecule. Any amount drawn from a pre-mixed vial contains both peptides in that fixed proportion, so the amount of one cannot be changed without changing the other. CJC-1295 without DAC has the least evidence: FDA found no pharmacology or nonclinical pharmacokinetic studies of it, there are no human data, and the only in-vivo record found is a qualitative rat detection study, so nothing can be said about what any amount of the mixture delivers. The evidence gives no safe or effective human dose or ratio for the blend, and neither ingredient provides a validated ceiling, because published human dosing of ipamorelin comes only from weight-based intravenous infusions in healthy men and bowel-surgery patients. No study has tested this pair together; the combination evidence found involves only related molecules (GHRP-6 or GHRP-2 given with GHRH in men, and GHRP-2 with the GHRH analogue JI-38 in GHRH-knockout mice).

No controlled trial has tested this combination in people. The comparison uses each ingredient's own studies, which often differ in route and population, so it is not a dosing guide.

Doses reported in online communities (untested)

Unverified, and not a recommendation. These are amounts people describe in online forums such as Reddit, collected so researchers can see how practice differs from the evidence. These forum accounts are not clinical evidence, even where they overlap studied doses. Products sold online as "research peptides" are not FDA approved, and their identity, purity and strength are not verified; they can be mislabeled, contaminated or wrongly dosed.

What people report

In the threads reviewed, people described injecting under the skin, from pre-mixed or separate vials, about 100 to 300 mcg of each peptide or about 100 to 850 mcg of blend, once or twice a day. The main disagreement was whether a stated amount meant each peptide or the whole blend. Reported side effects included flushing, racing heart and high blood pressure; swollen hands, dizziness and near-fainting; injection-site welts, dry skin and joint inflammation; broken sleep; a severe allergic reaction with hives; and higher glucose or insulin needs.

How this compares with the studies

The threads reviewed describe fixed microgram amounts injected under the skin. Published human dosing of ipamorelin comes only from intravenous infusions scaled to body weight in healthy men and bowel-surgery patients, CJC-1295 without DAC has no human dosing data, and the pair has never been studied together, so exposure, safety or efficacy cannot be compared between community amounts and any study.

Open questions a study would need to answer

What are the half-life and GH response of CJC-1295 without DAC injected under the skin in humans, alone and with ipamorelin?
Does this pair release GH synergistically in humans, as GHRH did with GHRP-6 or GHRP-2, and does the mass ratio in a vial change the response?
How often do hives and other hypersensitivity reactions occur with repeated subcutaneous use, and are they caused by either peptide or by impurities?

Threads consulted, checked 2026-09-26: CJC 1295 + Ipamorelin (r/Peptides) · My Experience with Ipamorelin/CJC-1295 (r/Peptides) · Mod GRF 1-29 / Ipamorelin no affect? (r/Peptides) · Racing Heart and high blood pressure after pin (r/Peptides) · Higher than normal Glucose on GHRPs and GHRHs (r/Peptides) · CJC-1295 + Ipamorelin with Testosterone Replacement Therapy (r/Peptides) · CJC-1295 and Ipamorelin stacked, what the combination actually does vs each alone (r/Peptides) · I'm a type 1 diabetic. I had got the cjc 1295/ipamorelin blend trying to gain weight (r/moreplatesmoredates)

Enforcement history

2023-09-29 · 503A Category 2 placement: FDA placed "CJC-1295" (form not specified) and ipamorelin acetate in Category 2 of its interim 503A bulk-substance policy, meaning substances that raise significant safety concerns. Ipamorelin acetate was placed in 503B Category 2 on the same date. (source)
2024-09-27 · Withdrawn from 503A Category 2: Both were removed from 503A Category 2 after the nominators withdrew, and FDA referred CJC-1295-related substances and ipamorelin to its Pharmacy Compounding Advisory Committee. Ipamorelin acetate remains in 503B Category 2 on FDA's page updated 2026-04-22. (source)
2024-10-29 · PCAC advisory vote (ipamorelin): The committee voted 0 yes, 12 no, 1 abstain on adding ipamorelin free base, and the same on ipamorelin acetate, to the 503A bulks list. No final FDA rule had been published as of this article. (source)
2024-12-04 · PCAC advisory vote (CJC-1295 without DAC): The committee voted 0 yes, 13 no on CJC-1295 free base and 1 yes, 12 no on CJC-1295 acetate for the 503A bulks list. No final FDA rule had been published as of this article. (source)
2022-03-10 · Inspection observations (FDA Form 483): FDA investigators at a Texas compounding pharmacy recorded that a CJC-1295 acetate/ipamorelin acetate injection lot was made with a non-pharmaceutical-grade CJC-1295 acetate component and distributed to patients nationwide. A Form 483 lists inspectional observations and is not a final agency determination. (source)
2026-10-30 · HHS draft enforcement-discretion policy (single-ingredient products only): HHS's draft interim policy on 503A compounding of six peptides (BPC-157, TB-500, KPV, MOTS-c, semax, epitalon) does not include CJC-1295 or ipamorelin, and it covers products with a single listed active ingredient, so this blend is outside it on both counts. The policy is not binding and adds nothing to the 503A bulks list. (source)

Side effects and warnings

Not catalogued yet.

Full lists are in the Scientific view.

Reported side effects

Not catalogued yet.

Interactions

Not catalogued yet.

Contraindications

Not catalogued yet.

Storage

No approved product exists for either ingredient or for the combination, so there is no label storage data.

General storage guidance commonly given for freeze-dried research peptides and powders, not stability data for this substance. Storage conditions and usable life depend on the specific product and formulation; follow its documented instructions.

Condition	Temperature
Temporary (transportation), in powdered form	15 °C – 25 °C / 59 °F – 77 °F
Short term (1–3 years)	2 °C – 8 °C / 36 °F – 46 °F
After reconstitution (28 days)	2 °C – 8 °C / 36 °F – 46 °F
Long term (2–5 years)	−20 °C / −4 °F or below

Product characteristics

Form: Two separate synthetic peptides combined in one vial, typically as a lyophilised powder; the ratio is set by whoever makes it

Compound information

Ingredient 1 is [D-Ala2, Gln8, Ala15, Leu27]-GRF(1-29)-NH2 (C152H252N44O42, 3367.9 g/mol); ingredient 2 is Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C38H49N9O5, 711.9 g/mol). FDA's 2024 review found the name CJC-1295 applied inconsistently to DAC and non-DAC peptides, so the label on a product is not a reliable guide to which is present.

Molecule, patents, enforcement history, full trial tables and compound details are in the Scientific view.

Common questions

What is CJC-1295 (no DAC) + Ipamorelin?

Products sold under this name put two lab-made peptides in one vial. A peptide is a short chain of amino acids (the building blocks of protein).

Is CJC-1295 (no DAC) + Ipamorelin FDA approved?

Not FDA approved for any use.

What have studies found?

No study has tested these two peptides together. No human doses of CJC-1295 without DAC are on record.
In one study, healthy men got ipamorelin into a vein. Growth hormone peaked at 0.67 hours and then dropped to very low levels. Half of the drug was gone from the body in about 2 hours (its half-life).

How was it dosed in studies?

Is it legal to buy as a "research peptide"?

Products sold as "research use only" or "not for human consumption" are not approved for use in people. That label does not make them legal to sell for human use, and their contents are not checked by any regulator.

References

This page summarises the published sources below. PeptideBasics101 does no original research. Trial doses and results are reported as the cited study or label reported them. Sources can themselves be wrong or superseded; if you find a statement here that does not match its source, please tell us through our corrections process. Sources were last checked on 2026-11-01.

Based on 9 published references

Clinical trial entries in the table above link to their ClinicalTrials.gov registry records. Spotted an error? See corrections.